Ignite Creation Date:
2024-05-06 @ 4:06 PM
Last Modification Date:
2024-10-26 @ 2:04 PM
Study NCT ID:
NCT04874844
Status:
UNKNOWN
Last Update Posted:
2021-05-10
First Post:
2021-04-12
Brief Title:
JY025 is a First-line Treatment for EGFR Mutated NSCLC Phase II and III Clinical Trials of Efficacy and Safety
Sponsor:
Organization:
Beijing Dongfang Biotech Co Ltd